Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

ONTX was downgraded by Zacks.com  from a “get” ranking to a “hold” score in a research note provided to investors on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on discovering and creating little particle medication candidates to deal with cancer cells. The Company‘s items under different stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research experts likewise recently discussed the firm. Noble Financial reissued a “purchase” rating and issued a $11.00 cost objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “buy” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating average rate of $2.90 and a two-hundred day moving typical price of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly revenues results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) incomes per share for the quarter, topping experts’ agreement estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and an unfavorable web margin of 8,294.27%. The firm had income of $0.06 million during the quarter, compared to the agreement quote of $0.06 million. During the same quarter in the prior year, the firm published ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the present year.

A variety of hedge funds have actually lately bought and sold shares of ONTX. GSA Capital Partners LLP purchased a brand-new placement in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Resources Administration LP purchased a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP got a new position in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and other institutional financiers have 13.36% of the firm’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which participates in the identification and also advancement of oncology therapeutics. It concentrates on discovering and also developing tiny particle medicine candidates to treat cancer cells. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Obtain a free copy of the Zacks research record on Onconova Therapeutics (ONTX).

For additional information regarding research offerings from Zacks Investment Research, go to Zacks.com.

This immediate news alert was created by narrative scientific research technology as well as economic data from Market in order to supply viewers with the fastest as well as most precise coverage. This story was assessed by Market’s content team before publication. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS TODAY?

Prior to you think about Onconova Therapeutics, you’ll want to hear this.

Market keeps track of Wall Street’s premier as well as best performing research analysts and also the stocks they suggest to their clients daily. Market has identified the 5 stocks that cover analysts are quietly murmuring to their clients to buy currently before the more comprehensive market catches on … and also Onconova Therapeutics had not been on the checklist.

While Onconova Therapeutics currently has a “Buy” ranking among analysts, top-rated analysts think these five stocks are better buys.

Comments are closed.